Bioniz - Spotlight

News

Bioniz Announces Oral Presentation at ASH 2020 of Positive Clinical Data of BNZ-1 for the Treatment of Refractory Cutaneous T-Cell Lymphoma

November 5, 2020

Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma

July 20, 2020

Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases

January 9, 2020

Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1

May 1, 2018

Bioniz Therapeutics Initiates Phase 1/2 Clinical Study of BNZ 1 in T-Cell Leukemia and Lymphoma

April 4, 2018

Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors

December 6, 2017

Bioniz Therapeutics to Present New Data at the 2017 ASH Annual Meeting

November 2, 2017

Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis

September 13, 2017

Bioniz Therapeutics Reports Top-Line Phase 1 Clinical Study Results for BNZ-1, A Novel Multi-Cytokine Inhibitor

July 19, 2017

Bioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical Development

December 20, 2016

Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors

August 1, 2016

Bioniz Therapeutics Appoints Fredrik Wiklund as Chief Operating Officer

May 3, 2016

Eric Carter, M.D., PH.D. Former CMO of Allergan, Joins Bioniz Therapeutics as Chairman of the Scientific and Clinical Advisory Board

April 12, 2016

Bana Jabri to Join Bioniz SAB

November 3, 2015

Publications Announced In JBC and PNAS

October 6, 2015